In addition, T-loop phosphorylation of CDK1/CDK2 was additively decreased by CT7001 and enzalutamide treatments, and a decrease in PolII phosphorylation was detected in tumours treated with CT7001 alone or in combination with enzalutamide. This evidence concerns the gene CDK2 and neoplasm.